Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 5/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.49 |
| ▸ | GBA1 | P04062 | 2/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | ACP1 | P24666 | 1/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23747915 | 0.83 | CYP1A2 (0.57) | SLC6A3ACP1TLR9MEN1MAPT | |
| SCHEMBL23747843 | 0.82 | SLC6A3 (0.49) | PDE5AHRH4SLC6A3GBA1ACP1 | |
| SCHEMBL23747842 | 0.81 | GBA1 (0.55) | PDE5ASLC6A3GBA1KDM1AACP1 | |
| SCHEMBL23747947 | 0.81 | TLR9 (0.60) | PDE5AHRH4GBA1ACP1TLR9 | |
| SCHEMBL23723287 | 0.80 | SLC6A3 (0.54) | PDE5AHRH4SLC6A3GBA1ACP1 | |
| SCHEMBL30125307 | 0.80 | SLC6A3 (0.54) | PDE5AHRH4SLC6A3GBA1ACP1 | |
| SCHEMBL23747914 | 0.80 | SLC6A3 (0.54) | PDE5AHRH4SLC6A3GBA1ACP1 | |
| SCHEMBL23723346 | 0.80 | PDE5A (0.48) | PDE5AHRH4SLC6A3ACP1TLR9 | |
| SCHEMBL30125141 | 0.80 | PDE5A (0.48) | PDE5AHRH4SLC6A3ACP1TLR9 | |
| SCHEMBL23747916 | 0.80 | HRH4 (0.59) | PDE5AHRH4ADORA3MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| EP-4100395-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | Trobio Therapeutics Pty Ltd (AU) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021155426-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | NQO2, TP53, ABL1 | PDE5A 784/4885HRH4 1715/4885SLC6A3 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.